Atlas Venture

Atlas Venture is a leading biotech venture capital firm focused on creating and building innovative life science companies. With over 30 years of experience, they have incubated over 70 startups and taken 40 companies public, including Intellia Therapeutics, Kymera Therapeutics, and Generation Bio. Atlas specializes in drug discovery and development, emphasizing areas like gene editing, oncology, and immunotherapy. Headquartered in Cambridge, Massachusetts, Atlas primarily targets U.S.-based startups but maintains a global vision, partnering with top scientific minds. They invest early, often leading seed and Series A rounds, with typical check sizes ranging from $5M to $20M. Atlas's approach is hands-on, actively incubating new ventures and co-founding companies with a strong operational focus. Key figures include Jean-François Formela, who has been instrumental in several high-profile exits and IPOs, and focuses on cutting-edge drug discovery technologies. Founders approaching Atlas should focus on breakthrough science with clear therapeutic applications, as the firm seeks to translate groundbreaking research into life-changing medicines.